Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …

Background Mosunetuzumab is a CD20× CD3 T-cell-engaging bispecific monoclonal
antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study …

PURPOSE Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or
refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been …

Introduction The introduction of anti-CD20 monoclonal antibody therapy with rituximab in the
1990s greatly improved outcomes for patients with B-cell malignancies. Disease resistance …

Patients with follicular lymphoma (FL) with early relapse after initial chemoimmunotherapy,
refractory disease, or histologic transformation (tFL) have limited progression-free and …

Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microenvironment that
is rich in nonmalignant immune cells. We applied single-cell RNA sequencing to …

Follicular lymphoma is the most common indolent non-Hodgkin's lymphoma, and because of
the incurable nature of this disorder, new therapies are constantly needed. The recently …

Purpose: We analyzed the utility of cell-free DNA (cfDNA) in a prospective population-based
cohort to determine the mutational profile, assess tumor burden, and estimate its impact in …

Tazemetostat is a selective, reversible, small‐molecule inhibitor of the histone
methyltransferase enzyme, enhancer of zest homolog 2 (EZH2). In this multicenter, open …

The phase 3 SELENE study evaluated ibrutinib+ chemoimmunotherapy (CIT; bendamustine
and rituximab [BR]; or rituximab, cyclophosphamide, doxorubicin, vincristine, and …